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Abbreviations: 
AIT Allergen Immunotherapy 
RCT Randomized controlled trials  
 
The allergist’s community  has recently celebrated 100 year of Allergen Immunotherapy 
(AIT). Unfortunately the implemention of this treatment is still impaired by some  challenges. 
With the diversity of definitions, methodology and different allergen products used, research 
studies have produced conflicting outcomes. This has resulted in confusion about the 
benefits and risks of AIT amongst policymakers and professionals, as well as in the variable 
availability of AIT products, regulation and reimbursement policies globally. In 2015 EAACI 
initiated the AIT Guidelines project as part of the Presidential plan in order to settle the 
controversies. The result has been a rigorous process of guideline development (1) in order 
to inform and facilitate high quality clinical practice for AIT. The Guidelines are based on 
some key pillars: an evidence–based approach, involvement of multidisciplinary and 
multiprofessional groups, recommendations centred on the patient, highlighting the benefits 
and harms of AIT. In the development process accountability to evidence meant paying 
attention to transparency and independency of the process. Rigour of development was 
reflected in the provision of search strategy details, a description of the process for external 
review and a plan for future update of the guidelines. Although these Guidelines were 
funded by EAACI, the funder had no influence on the guideline production process, its 
contents nor on the decision to publish. Taskforce members’ conflicts of interest were 
declared and taken into account. Final decisions about strength of evidence for 
recommendations were checked by the methodologists who had no conflicts of interest in 
this area.  
The process of producing these guidelines has involved recognition of the importance of 
following a structured process (2), created a valuable opportunity for clinicians, researchers, 
methodologists and patient representatives to work together, and has allowed a shared 
appreciation of the need to also consider implementation considerations so the benefits of 
AIT can be safely realized by our patients. We have had to address some challenges, 
shared with other discplines (3), that it would be useful to discuss. Firstly, the evidence-
based approach is often seen as too demanding so we adopted a user-friendly approach to 
facilitate appraisal of  the key evidence to generate recommendations (4). Secondly, 
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guidelines are often seen as very narrow so we carefully considered and incorporated the 
views of other stakeholders in formulating recommendations. Thirdly a criticism was raised 
as to whether the time, effort and expense involved were worthwhile and whether it would 
make a difference to the ultimate recommendations. We suggest that a rigorous and 
transparent process provides good value by adding confidence on the validity of the 
recommendations for practicing clinicians.  
 
Approach to generating the Guidelines 
The EAACI AIT Steering Group decided to employ the Appraisal of Guidelines for Research 
and Evaluation (AGREE II) approach to generate the AIT guidelines (2), as this was 
considered best tailored to generate guidelines for clinicians. This framework ensures 
appropriate representation of the full range of stakeholders, a careful search for and critical 
appraisal of the relevant literature, a systematic approach to the formulation and 
presentation of recommendations and steps to minimize the risk of bias at each step of the 
process.  
The initial full range of clinical questions that were considered important for the guidelines 
were rationalized into an over-arching question for each guideline, namely the effectiveness, 
safety and cost-effectiveness of allergen immunotherapy for allergy prevention, food allergy, 
allergic rhinitis, asthma, and venom allergy. These questions were then pursued through 
developing systematic reviews led by independent methodologists. We continued to track 
relevant evidence after our systematic review cut-off dates.   
We graded the strength and consistency of key findings from the systematic reviews and, 
where possible and appropriate, performed meta-analyses using random-effects models to 
take into account the heterogeneity of findings. This approach was the basis to formulate 
evidence-based recommendations for clinical care. The Oxford Centre for Evidence-based 
Medicine (4) methodology was used as a practical approach that could be readily utilized by 
the EAACI Taskforce members. This involved both formulating the recommendations and 
detailing the strength of evidence underpinning each recommendation. Where the 
systematic reviews did not cover the clinical area, we took a hierarchical approach to review 
other evidence until we could formulate a recommendation as follows: (i) other systematic 
reviews on the subject to see if they provided any further clarity on the topic; (ii) randomized 
controlled trials (RCT) within these systematic reviews; (iii) other RCTs known to Taskforce 
members; and (iv) a consensus-based approach within the Taskforce. This evidence was 
graded and clearly labelled in the recommendation tables. When there were insufficient 
pediatric data, we extrapolated from the adult recommendation where it was biologically 
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likely that the intervention would also be effective in children, but in so doing, the 
recommendation was downgraded by at least one level.  
A draft of each Guideline was externally peer-reviewed by invited experts from a range of 
organizations, countries and professional backgrounds. Additionally, each draft guideline 
was made available on the public domain of the EAACI Website for a three week period in 
May 2017 to allow a broader array of stakeholders to comment. All feedback was considered 
by Taskforce members and final revisions were made in the light of the feedback received.  
 
How to use the Guidelines 
These Guidelines (5-8) are aimed at healthcare professionals and should help them deliver 
better clinical care with more effective and safe use of AIT. Professionals still need to utilize 
their clinical training, experience and judgment to deliver personalized healthcare. The 
Guidelines provide answers to key clinical questions (see Box 1) summarizing the evidence 
for and against different therapies. Recommendations are clearly described but may not be 
appropriate for all people, patients and situations. A key conclusion from the Guidelines is 
the need to limit practice to the use of high quality, standardized AIT products with good 
evidence of effectiveness - a product-specific approach - since many available products are 
not supported by sufficient evidence of efficacy.  
 
Future challenges  
The use of AIT is currently restricted by the limited availability of high quality, standardized 
products with good evidence of effectiveness (9,10). This could be improved with the 
widespread adoption by industry and specialists of the best regulatory framework. Special 
consideration will however be required for rare allergens where it may not be possible to 
undertake large clinical trials. Another key limitation is access to AIT. Greater awareness of 
the need for and availability of AIT within primary care and partnership with specialists will be 
necessary to overcome this (11). Clinical care pathways and better quality standards of care 
are required to faciliate this. The Guidelines highlight many gaps in the evidence base, 
particularly around the longterm effectiveness of AIT, the evidence for effectiveness of many 
commercial products and a shortage of data in children and for health economic 
considerations.  We hope that these Guidelines will catalyze the commissioning of research 
to fill these evidence gaps. EAACI plans to update these guidelines with recommendations 
informed by evidence published over the five years 2017-2022.  
The AIT Guidelines and underpinning systematic reviews can all be accessed at 
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http://www.eaaci.org/resources/guidelines/ait-guidelines-part-2.html (last accessed 17th 
January 2018).  
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Box 1. Key points from each guideline 
Prevention (5) 
• A three year course of Allergen Immunotherapy (AIT) (subcutaneous immunotherapy 
[SCIT] or sublingual immunotherapy [SLIT]) can be considered in children with 
moderate to severe allergic rhinitis and grass/birch pollen allergy, not sufficiently 
controlled with optimal pharmacotherapy, for short-term (i.e. up to 2 years post-
treatment) (Grade A) and possibility long-term (Grade B) prevention of asthma 
symptoms in addition to improving the control of AR.  
• Only AIT products with documented effect in patients with the relevant pollen allergy 
should be used and a product-specific evaluation of clinical efficacy and preventive 
effects is recommended. 
• Before initiating AIT, the possible benefits including the beneficial effects of 
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controlling allergic rhinitis symptoms and the asthma preventive effect, 
disadvantages, potential harms, patients’ preferences (SCIT or SLIT-tablets/ SLIT-
drops), patients’ adherence to treatment and costs should be discussed with the 
patient / family on an individual basis. 
• There is an urgent need for more high-quality clinical trials on prevention in AIT.  
Venom (6) 
• Venom immunotherapy (VIT) is indicated in venom allergic individuals following 
moderate to severe systemic reactions (Grade A for adults, B for children). 
• VIT is also recommended to reduce systemic allergic reactions in adults with skin 
symptoms only when quality of life is impaired (Grade A). 
• VIT is safe for patients with special conditions, such as mastocytosis (Grade C). 
• Pre- treatment with H1 antihistamines should be used to prevent large local reactions 
(Grade A).  
• A 12-week maintenance injection interval can be recommended in life-long VIT 
(Grade C). 
• A 200µg maintenance dose should be used for patients still reacting while on a 
conventional (100µg) dose (Grade C). 
• Life-long VIT can be recommended in patients at high risk for relapse (Grade C). 
• Considerable gaps were identified in the evidence base emphasizing the need for 
future well-designed studies, particularly in the paediatric population. 
IgE-mediated food allergy (7) 
• Allergen Immunotherapy for food allergy (FA-AIT) should only be performed by 
experienced personnel in research centers or in clinical centers with an extensive 
experience in food allergy AIT.  
• Food allergy allergen immunotherapy (FA-AIT) should be considered for children 
from around 4 - 5 years of age with a persistent IgE-mediated food allergy to cow’s 
milk (Grade A), hen’s egg (Grade B) or peanut (Grade A) to increase the threshold of 
reactivity while on therapy. A benefit post-discontinuation is suggested but not 
confirmed.  
• Oral immunotherapy (OIT) affords better efficacy than sublingual immunotherapy 
(SLIT) but OIT is associated with higher frequency of adverse events than SLIT 
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although most are not severe.  
• The initial FA-AIT dosage and each increased dosage during the build-up phase 
should be performed in clinical setting. 
• Patients and their families should be provided with information about the use of AIT 
for IgE-mediated food allergy to allow them to make an informed decision about the 
therapy (Grade D).  
• Longitudinal, prospective, well-designed studies are needed to fill the many gaps yet 
to be addressed with the final goal of extending FA- AIT protocols in clinical practice 
as standard medical therapy. 
• There is a paucity of evidence for use of FA-AIT in adults. 
Allergic rhinoconjunctivitis (8) 
• AIT should be considered in patients with allergic rhinitis (AR), with or without 
conjunctivitis; evidence of IgE-sensitization to one or more clinically relevant 
allergens; and moderate-to-severe symptoms despite regular and/or avoidance 
strategies. 
• An individual product-based evaluation of evidence for efficacy is recommended 
before treatment with a specific product is initiated. 
• The following can be recommended for AR for short-term benefit: 
o Continuous SCIT for seasonal (Grade A for adults, B for children) or perennial 
(Grade B for adults, C for children) allergens.  
o Pre- and pre-/co-seasonal SCIT (Grade A for adults, B for children). 
o Modified (allergoids) and unmodified allergen SCIT extracts (Grade A for 
adults, B for children).  
o SLIT aqueous solutions for grass and tree pollens (Grade B for adults, A in 
children). 
• The following can be recommended for AR for short- and long-term benefit:  
o Continuous grass pollen SCIT (Grade A for adults, B for children). 
o Continuous grass pollen SLIT tablets or SLIT solution (Grade A). 
o HDM SLIT tablet (but not aqueous solution) for short-term (Grade A) and 
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long-term benefit (Grade B for adults, C for children). 
• To achieve long-term efficacy, it is recommended that a minimum of 3 years of 
therapy is used (Grade A). 
• SCIT and initial SLIT dosage should be administered by competent staff with patients 
waiting in the clinic for at least 30 minutes after dose (Grade C). 
• Many gaps in the evidence base exist, particularly around long-term benefit and use 
in children. 
Grades A to D represents the strength of the recommendation with A being the strongest 
with recommendations being based on consistent, randomized, controlled trial data; B being 
based on two groups, non-randomized studies (e.g., cohort, case–control); C being based 
on one group, non-randomized studies (e.g., before and after); and D being based on expert 
opinion (4). 
Box 2. How can we facilitate the implementation of AIT Guidelines? 
Improving access to Allergen Immunotherapy (11) 
• Education and training for primary care personal in clinical allergy, including Allergen 
Immunotherapy (AIT).  
• Stratifying patients into those who can be managed exclusively in primary care and those 
with more problematic disease who need referral to specialist care.  
• Development of clinical care pathways and better quality standards of care to facilitate 
integrated care systems between primary and specialist care providers.  
Regulation of allergen products (9,10) 
• Improved and standardized definitions for future AIT trials.  
• Harmonization of the regulations that are applied across Europe to promote the use of AIT 
products with proven quality, safety and efficacy.  
• Special considerations for rare allergens where it is not viable to undertake very large 
RCTs to demonstrate efficacy and safety of AIT with the product. 
• Improved analytical procedures to enable more precise characterizations of allergen 
products to ensure standardization of AIT formulations.  
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